Early Real-World Biomarker Trajectories After Sibeprenlimab Initiation in Patients with IgAN: A Multicenter Observational Cohort Study (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0495; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Supportive therapies included RAAS blockers, sparsentan, atrasentan, and SGLT2i. Conclusion Sibeprenlimab initiation was associated with progressive early reductions in proteinuria and albuminuria in a real-world IgAN cohort receiving complex multidrug supportive regimens. These findings support the integration of APRIL inhibition into routine nephrology practice and highlight the evolving role of multidrug therapeutic strategies in IgAN management."
Biomarker • Clinical • Observational data • Real-world • Real-world evidence • Glomerulonephritis • IgA Nephropathy • Nephrology • Renal Disease
|
|
George Vasquez-Rios; Luis F. Sanchez Russo; Raymond K. Hsu; Kartik Kalra; Suneel M. Udani; Abdallah Sassine Geara; Wonsuk Oh; Steven G. Coca; Kirk N. Campbell; Arun Rajasekaran
|